🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Terence Z. Wong

Alzheimer’s Disease Neuroimaging Initiative

ORCID: 0000-0002-5236-9139

Also affiliated with Duke Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients”.

The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients

Journal of Geriatric Oncology(2023)10.1016/j.jgo.2023.101474
N/A
0.693DataRank · unranked
18 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Helga S. Marques +8 more

Association Between RT-Induced Changes in Lung Tissue Density and Global Lung Function

UNC Libraries(2020)10.17615/en6t-kw22
N/A
0DataRank · unranked
0 citations

K. Light, Jinli Ma, Terence Z. Wong, Rodney J. Foltz, Junan Zhang +5 more

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4064
N/A
0DataRank · unranked
13 citations

Michelle Weitz, Paul J. Catalano, Michael K. Gibson, Lakshmi Rajdev, Onkar V. Khullar +15 more

Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps5098
N/A
0DataRank · unranked
3 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps267
N/A
0DataRank · unranked
2 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4004
N/A
0DataRank · unranked
21 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +15 more

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4020
N/A
0DataRank · unranked
13 citations

Paul J. Catalano, George A. Fisher, Daniel B. Rubin, Andrei Iagaru, David S. Klimstra +11 more

A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps9591
N/A
0DataRank · unranked
4 citations

Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer L. Guerriero, Thomas U. Marron +8 more

A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4185
N/A
0DataRank · unranked
0 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Shaalan Beg +9 more

Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment

BMC Geriatrics(2023)10.1186/s12877-023-04175-8
N/A
0DataRank · unranked
13 citations

Sara Maestri, Silvia Serino, Elisa Pedroli, Marco Stramba‐Badiale, Giuseppe Riva +95 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5118
N/A
0DataRank · unranked
1 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps402
N/A
0DataRank · unranked
0 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Data from Dynamic Contrast-enhanced Magnetic Resonance Imaging as a Predictor of Clinical Outcome in Canine Spontaneous Soft Tissue Sarcomas Treated with Thermoradiotherapy

(2023)10.1158/1078-0432.c.6518202.v1
N/A
0DataRank · unranked
0 citations

Michaël Lora‐Michiels, Jeanie M. Poulson, Lan Lan, Dahio Yu, Linda Sanders +8 more

Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4133
N/A
0DataRank · unranked
0 citations

Elizabeth A. Handorf, Pamela L. Kunz, Emel Alkım, Lauren M. Burke, Paul J. Catalano +10 more

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4651
N/A
0DataRank · unranked
11 citations

Michelle Weitz, Michael K. Gibson, Lakshmi Rajdev, Onkar V. Khullar, Steven H. Lin +13 more

A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.4000
N/A
0DataRank · unranked
23 citations

Noah Graham, Michael K. Gibson, Lakshmi Rajdev, Anuradha Chakravarthy, Onkar V. Khullar +13 more